Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2003

View Archived Issues

Phase I interim safety data reported for Reolysin in malignant glioma

Results reported for NBI-3001 in glioblastoma

Cytogen regains rights to ex vivo prostate cancer immunotherapy

Velcade enters phase II trial in colorectal cancer

MoliChem reacquires rights to Moli-1901

AEterna acquires Zentaris from Degussa

Zindaclin receives further E.U. approvals

NexMed completes dosing in two-year rat carcinogenicity study

Crucell regains rights to anti-CD46 antibody

IND filed for EOS-200-4

Topamax sNDA submitted for migraine prevention

Xenova advances two new programs into preclinical research

Restasis receives FDA approval

Amylin to acquire rights to Restoragen's GLP-1 program

Inspra meets primary endpoints in EPHESUS trial

COX-2-specific inhibitor LAS-34475 compares favorably to naproxen in osteoarthritis

HDAC inhibitor MS-275 active against pediatric solid tumors in vitro and in vivo

Third phase III MorphiDex trial fails to meet endpoints

Pharmacokinetic, toxicity and efficacy data for LEraf-AON in animals

Highly selective CB2 receptor ligand emerges from SAR studies at U.S. universities

New central muscle relaxant/antiinflammatory/analgesic advanced to clinical evaluation at GSK

Novel caspase inhibitors and their use reported by Vertex

Anticonvulsant compounds in early development at UCB

Ono patent covers new endothelial differentiation gene-1 (EDG1) agonists

New JAK3 inhibitors identified at AstraZeneca

Nonredox antiobesity cobalt porphyrin complexes discovered at MitoKor

Modified antisense oligonucleotides targeting ICAM-1 and VCAM-1 show potential in IBD

Galderma describes new series of vitamin D analogues for skin disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.